Dana-Farber $15M Settlement: Admission, Terms, and Retractions

The Dana-Farber Cancer Institute agreed on December 16, 2025 to pay $15 million to settle federal allegations that its researchers manipulated images in studies funded by National Institutes of Health grants and then used that tainted work to secure additional federal funding. The deal, announced by the U.S. Department of Justice, resolved a False Claims Act lawsuit filed by Sholto David, a British molecular biologist who had publicly documented image problems in dozens of Dana-Farber publications starting in January 2024.¹

What Dana-Farber Admitted

The conduct at issue ran from 2014 to 2024. Dana-Farber acknowledged that researchers working under two principal investigators produced publications containing images that had been reused, duplicated, rotated, magnified, or stretched to depict experimental conditions other than the ones they actually showed.² Fourteen publications were tied to the first investigator’s grants; one 2015 article in Nature Medicine was tied to the second.³

The False Claims Act theory was straightforward. By certifying compliance with NIH grant terms while spending federal money on research that produced manipulated results, Dana-Farber caused false claims to be submitted to the government. The institute also admitted that one of the researchers applied for and received four additional NIH grants by citing a published article without disclosing that it contained misrepresented data.¹

The Researchers Named

The settlement itself refers to the two principal investigators only as “Researcher 1” and “Researcher 2.” Reporting by STAT News and Retraction Watch identified Researcher 1 as Kenneth Anderson, a hematologist who directs the Jerome Lipper Multiple Myeloma Center at Dana-Farber, and Researcher 2 as Ruben Carrasco, a physician-scientist focused on cancer development.⁴

Anderson was principal investigator on six NIH grants that funded the 14 publications named in the case, which appeared between 2014 and 2024 in journals including Blood, Leukemia, and Clinical Cancer Research. The settlement stated he “failed to exercise sufficient oversight” of the researchers under him.⁵ Carrasco was identified as the senior author of the 2015 Nature Medicine paper, which received two image-related corrections in 2024 and which he cited in later grant applications without disclosing the data issues.³

Neither researcher was reported to have been terminated or to have resigned in connection with the settlement. Dana-Farber’s research integrity officer declined to comment on personnel matters.⁶

How the Case Started

Sholto David runs a blog called For Better Science and has flagged image problems in more than 2,000 papers on PubPeer, a site where scientists comment on published research.⁷ On January 2, 2024, he published a post titled “Dana-Farberications at Harvard University,” laying out evidence of duplicated and altered images across dozens of papers by Dana-Farber researchers, including members of senior leadership. Before going public, he reported his findings to Dana-Farber’s Research Integrity Office, the study authors, and the journals involved.⁸

In April 2024, David filed a qui tam lawsuit under the False Claims Act, which allows private individuals to sue on behalf of the government when they uncover fraud against federal programs. His complaint identified a “pattern of fraud” across 95 studies by Dana-Farber researchers and was filed under seal, remaining confidential for roughly 20 months while the DOJ investigated.³

What the Settlement Requires

Dana-Farber must pay the $15 million within 30 days of the agreement’s effective date, with interest accruing at 4.375 percent per year from August 27, 2025. Of that total, $8,571,428.57 is designated as restitution to the United States.⁵ David received 17.5 percent of the settlement, or $2,625,000, as his whistleblower share, and Dana-Farber agreed to pay $328,498.53 in attorneys’ fees for his legal team.¹

The agreement states that the resolved claims are allegations only and that “there has been no determination of liability.” At the same time, Dana-Farber formally “admits, acknowledges, and accepts responsibility” for the conduct described, including the failure to ensure adequate oversight and the expenditure of federal funds on research containing manipulated data.⁵ The DOJ credited Dana-Farber for cooperating, voluntarily disclosing additional misconduct, producing materials without a subpoena, and implementing remedial measures.² The institute also committed to identifying and repaying any additional unallowable costs to the government within 90 days. The published settlement does not mention a Corporate Integrity Agreement or any risk of exclusion from federal health programs.

Retractions and Corrections

Dana-Farber moved quickly on the flagged papers. By January 22, 2024, the institute confirmed it was asking journals to retract six studies and correct 31 more out of the 58 papers David had identified.⁹ Anderson was senior author on six of the seven papers ultimately retracted, in Cancer Research and the Journal of Immunology.⁶ Corrections and editorial notes appeared in Nature Medicine, Nature Immunology, Clinical Cancer Research, and the Proceedings of the National Academy of Sciences. As of mid-2024, only about 11 articles had editorial notes visible on their web pages, short of the 31 corrections the institute had pledged, and a Dana-Farber spokesperson declined to provide a complete list.¹⁰

Leadership Context

Benjamin Ebert became Dana-Farber’s CEO on October 1, 2024. He said the institute had “developed and implemented a number of initiatives to enhance our research integrity efforts, improve data hygiene, and prevent avoidable errors in scientific papers,” with some efforts predating the investigation.⁴

Ebert succeeded Laurie Glimcher, who had led Dana-Farber since 2016 and announced on September 3, 2024 that she would step down. Glimcher said she wanted to refocus on cancer immunology research and spend more time with family.¹¹ Glimcher and Chief Operating Officer William Hahn were among the four senior Dana-Farber researchers whose work David had flagged in January 2024, and a 2006 paper on which Glimcher was corresponding author was retracted by Science in April 2024.¹² Dana-Farber stated that the work of Glimcher and Hahn was not part of the December 2025 settlement.⁴

1
U.S. Department of Justice. Dana-Farber Cancer Institute Agrees to Pay $15 Million to Settle Fraud Allegations Related to Scientific Research Grants
2
U.S. Department of Justice. Dana-Farber Cancer Institute Agrees to Pay $15M to Settle Fraud Allegations Related to Scientific Research Grants
3
Retraction Watch. Dana-Farber Settlement False Claims Act Image Manipulation
4
STAT News. Dana-Farber $15 Million Settlement Manipulated Data
5
U.S. Department of Justice. Settlement Agreement, USA v. Dana-Farber Cancer Institute
6
NBC News. Cancer Institute Dana-Farber Retracts Studies Errors
7
STAT News. Sholto David Profile Dana-Farber Retractions
8
Whistleblower LLC. Manipulated Research Data Leads to $15 Million DOJ Settlement
9
STAT News. Dana-Farber Research Retractions Corrections
10
Cancer Therapy Advisor. Corrections Papers Dana-Farber Researchers
11
Dana-Farber Cancer Institute. Dana-Farber President and CEO Laurie Glimcher Announces Her Plans to Step Down
12
The Harvard Crimson. Dana-Farber CEO Steps Down